<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418002</url>
  </required_header>
  <id_info>
    <org_study_id>CAQW051A2102</org_study_id>
    <nct_id>NCT00418002</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of AQW051 in Elderly Healthy Volunteers.</brief_title>
  <official_title>A Randomized, Double-Blind, Ascending Dose, Placebo-Controlled Single Dose Study in Non-Smoking Healthy Elderly Subjects Interleaved With a 2-Week Multiple Once Daily Dose Study to Explore Safety, Tolerability, Pharmacokinetics and Cognitive Effects After Oral Administration of AQW051</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety and tolerability of AQW051 administered in&#xD;
      single and multiple doses to elderly healthy volunteers. In addition, pharmacokinetic effects&#xD;
      will be assessed and the possible effects on cognition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics at the end of the study.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of AQW051 on cognition as assessed by a computerized cognitive test battery.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess a potential food effect on pharmacokinetics of AQW051.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the drug abuse liability potential of AQW051.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AQW051</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and postmenopausal female subjects between 60 to 80 years of age and in&#xD;
             good health as determined by past medical history.&#xD;
&#xD;
          -  Postmenopausal women must have no regular menstrual bleeding for at least 1 year prior&#xD;
             to inclusion.&#xD;
&#xD;
          -  Male subjects must be using a double-barrier local contraception.&#xD;
&#xD;
          -  Body mass index must be within the range of 18 to 33. Subjects must weigh at least 50&#xD;
             kg to participate in this study.&#xD;
&#xD;
          -  The regular intake of concomitant drugs including thyroxine, paracetamol, low dose&#xD;
             non-steroidal anti-inflammatory drugs, lipid lowering drugs, vitamins and dietary&#xD;
             supplements without caffeine and nicotinic acid, and hormone replacement therapy is&#xD;
             allowed, if on stable treatment for at least 3 months. Intake of nutritional&#xD;
             supplements (e.g. omega-3, vitamins, minerals, cod-liver oil) is allowed.&#xD;
&#xD;
          -  Able to communicate well with the investigator, to understand and comply with the&#xD;
             requirements of the study. Understand and sign the written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smokers (use of tobacco products in the previous 3 months).&#xD;
&#xD;
          -  Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter&#xD;
             medication (e.g. herbal supplements) within 2 weeks prior to study start except noted&#xD;
             previously&#xD;
&#xD;
          -  Use of any central nervous system active drug and anticholinergic drugs during the&#xD;
             previous 3 months and use of any drug or treatment known to cause major organ system&#xD;
             toxicity during the previous 3 months is prohibited.&#xD;
&#xD;
          -  A past personal or close family medical history of clinically significant cardiac&#xD;
             abnormalities.&#xD;
&#xD;
          -  Current diagnosis of cardiac arrhythmia derived from ECG and/or Holter ECG.&#xD;
&#xD;
          -  Current diagnosis of cardiovascular disease.&#xD;
&#xD;
          -  Current diagnosis or history of autonomic dysfunction (e.g. history of fainting,&#xD;
             orthostatic hypotension, sinus arrhythmia).&#xD;
&#xD;
          -  History of Acute or chronic bronchospastic disease (including asthma and chronic&#xD;
             obstructive pulmonary disease) Clinically significant drug allergy or history of&#xD;
             atopic allergy (asthma, urticaria, eczematous dermatitis) Known hypersensitivity or&#xD;
             severe adverse event to darifenacin or similar drugs Any surgical or medical condition&#xD;
             which might significantly alter the absorption, distribution, metabolism or excretion&#xD;
             of drugs or which may jeopardize participation in the study Immunodeficiency diseases,&#xD;
             including a positive HIV (ELISA and Western blot) test result Positive Hepatitis B&#xD;
             surface antigen (HBsAg) or Hepatitis C test result. Drug or alcohol abuse within the&#xD;
             12 months prior to dosing.&#xD;
&#xD;
          -  Diagnosis of cognitive impairment (Mini Mental State Exam &lt; 27).&#xD;
&#xD;
          -  History or current diagnosis of a cerebrovascular disease (e.g., stroke, transient&#xD;
             ischemic attacks, aneurysms).&#xD;
&#xD;
          -  Current DSM-IV diagnosis of major depression and/or any other DSM-IV Axis 1 diagnosis&#xD;
             that may interfere with the evaluation of the patient's response to study medication,&#xD;
             including other primary neurodegenerative dementia, schizophrenia, or bipolar&#xD;
             disorder.&#xD;
&#xD;
          -  History or current diagnosis of an active, uncontrolled seizure disorder.&#xD;
&#xD;
          -  History of head injury or any other neurological disorder.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Horsham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>January 3, 2007</study_first_submitted>
  <study_first_submitted_qc>January 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2007</study_first_posted>
  <last_update_submitted>June 21, 2007</last_update_submitted>
  <last_update_submitted_qc>June 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2007</last_update_posted>
  <keyword>Single-rising dose , multiple rising dose, elderly, cognitive, , pharmacokinetic, impairment.</keyword>
  <keyword>Healthy elderly male and female subjects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

